{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:51:41Z","timestamp":1769604701443,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00228-017-2230-6","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T14:14:32Z","timestamp":1489068872000},"page":"727-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Brivaracetam population pharmacokinetics in children with epilepsy aged 1\u00a0month to 16\u00a0years"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-3005","authenticated-orcid":false,"given":"Rik","family":"Schoemaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"2230_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1212\/WNL.0b013e31822cfc90","volume":"77","author":"AK Ngugi","year":"2011","unstructured":"Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR (2011) Incidence of epilepsy: a systematic review and meta-analysis. Neurology 77:1005\u20131012","journal-title":"Neurology"},{"key":"2230_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1586\/14737175.7.2.179","volume":"7","author":"SM Hadjiloizou","year":"2007","unstructured":"Hadjiloizou SM, Bourgeois BF (2007) Antiepileptic drug treatment in children. Expert Rev Neurother 7:179\u2013193","journal-title":"Expert Rev Neurother"},{"key":"2230_CR3","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammels P, Bajjalieh SM, Matagne, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci 101:9861\u20139866","journal-title":"Proc Nat Acad Sci"},{"key":"2230_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","volume":"75","author":"JA French","year":"2010","unstructured":"French JA, Costantini C, Brodsky A, von Rosenstiel P (2010) Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 75:519\u2013525","journal-title":"Neurology"},{"key":"2230_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","volume":"54","author":"W Paesschen van","year":"2013","unstructured":"van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P (2013) Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 54:89\u201397","journal-title":"Epilepsia"},{"key":"2230_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S (2014) Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 55:57\u201366","journal-title":"Epilepsia"},{"key":"2230_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S (2014) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 55:47\u201356","journal-title":"Epilepsia"},{"key":"2230_CR8","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P (2015) A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 56:1890\u20131898","journal-title":"Epilepsia"},{"key":"2230_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","volume":"63","author":"ML Sargentini-Maier","year":"2007","unstructured":"Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A (2007) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 63:680\u2013688","journal-title":"Br J Clin Pharmacol"},{"key":"2230_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66:71\u201375","journal-title":"Br J Clin Pharmacol"},{"key":"2230_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1124\/dmd.107.017129","volume":"36","author":"ML Sargentini-Maier","year":"2008","unstructured":"Sargentini-Maier ML, Espi\u00e9 P, Coquette A, Stockis A (2008) Pharmacokinetics and metabolism of [14C]-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36:36\u201345","journal-title":"Drug Metab Dispos"},{"key":"2230_CR12","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/epi.13433","volume":"57","author":"A Stockis","year":"2016","unstructured":"Stockis A, Hartstra J, Mollet M, Hadi S (2016a) Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia 57:1288\u20131293","journal-title":"Epilepsia"},{"key":"2230_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.275","author":"C Otoul","year":"2016","unstructured":"Otoul C, Watanabe S, McCabe S, Stockis A (2016) Relative bioavailability and bioequivalence of brivaracetam 10 mg\/mL oral solution and 50 mg film-coated tablet. Clin Pharm Drug Dev. doi:\n10.1002\/cpdd.275","journal-title":"Clin Pharm Drug Dev"},{"issue":"Suppl. s1","key":"2230_CR14","first-page":"390","volume":"14","author":"E Liu","year":"2014","unstructured":"Liu E, Hepner A, Dilley D, Stockis A, Daniels A (2014) Safety and tolerability of adjunctive brivaracetam administered as oral solution in pediatric patients aged \u22651 month to 16 years with epilepsy. Epilepsy Curr 14(Suppl. s1):390\u2013391","journal-title":"Epilepsy Curr"},{"key":"2230_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"2230_CR16","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832\u20131843","journal-title":"Clin J Am Soc Nephrol"},{"key":"2230_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","volume":"58","author":"B Green","year":"2004","unstructured":"Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119\u2013133","journal-title":"Br J Clin Pharmacol"},{"key":"2230_CR18","volume-title":"NONMEM Users Guides","year":"2009","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (eds) (2009) NONMEM Users Guides. Icon Development Solutions, Ellicott City"},{"key":"2230_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction into the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani R (1993) An introduction into the bootstrap. Chapman & Hall, London, UK, New York"},{"key":"2230_CR20","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2007","unstructured":"R Development Core Team (2007) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"2230_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/A:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15:1463\u20131468","journal-title":"Pharm Res"},{"key":"2230_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79:241\u2013257","journal-title":"Comput Methods Prog Biomed"},{"key":"2230_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2230_CR24","first-page":"1434","volume":"17","author":"MO Karlsson","year":"2008","unstructured":"Karlsson MO, Holford N (2008) A tutorial on visual predictive checks. PAGE 17:1434 [\nwww.page-meeting.org\/?abstract=1434\n\n]","journal-title":"PAGE"},{"key":"2230_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jcph.761","volume":"56","author":"R Schoemaker","year":"2016","unstructured":"Schoemaker R, Wade J, Stockis A (2016) Brivaracetam population pharmacokinetics and exposure response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol 56:1591\u20131602","journal-title":"J Clin Pharmacol"},{"key":"2230_CR26","unstructured":"Center for Disease Control and Prevention, National Health and Nutrition Examination Survey (2013) The 1999\u20132004 dual energy X-ray absorptiometry (DXA) multiple imputation data files and technical documentation. \nhttp:\/\/wwwn.cdc.gov\/nchs\/nhanes\/dxx\/dxa.aspx\n\n (accessed 8 May 2013)"},{"key":"2230_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17\u201320","journal-title":"Clin Pharmacol Ther"},{"key":"2230_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/dmd.115.069161","volume":"44","author":"A Stockis","year":"2016","unstructured":"Stockis A, Watanabe S, Scheen AJ, Tytgat D, Gerin B, Rosa M, Chanteux H, Nicolas JM (2016b) Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos 44:792\u2013799","journal-title":"Drug Metab Dispos"},{"key":"2230_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","volume":"52","author":"X Wen","year":"2001","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT (2001) In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 52:547\u2013553","journal-title":"Br J Clin Pharmacol"},{"key":"2230_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","volume":"37","author":"PE Rolan","year":"1994","unstructured":"Rolan PE (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37:125\u2013128","journal-title":"Br J Clin Pharmacol"},{"key":"2230_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/epi.12745","volume":"55","author":"SJ Petty","year":"2014","unstructured":"Petty SJ, Kantor S, Lawrence KM, Berkovic SF, Collins M, Hill KD, Makovey J, Sambrook PN, O'Brien TJ, Wark JD (2014) Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study. Epilepsia 55:1551\u20131557","journal-title":"Epilepsia"},{"key":"2230_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","volume":"46","author":"E Pigeolet","year":"2007","unstructured":"Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A (2007) Population pharmacokinetics of levetiracetam in Japanese and western adults. Clin Pharmacokin 46:503\u2013512","journal-title":"Clin Pharmacokin"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2230-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:38:30Z","timestamp":1589737110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2230-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}